The role of chemistry in the success of oligonucleotides as therapeutics

• Pawan Kumar and
• Tom Brown

Beilstein J. Org. Chem. 2022, 18, 197–199, doi:10.3762/bjoc.18.22

• forefront of solving these issues, and have introduced many chemically modified nucleotides into oligonucleotides to increase their binding affinity toward RNA targets, and to improve their stability against nucleases to slow down degradation. This strategy has been successful, and most oligonucleotide

• -based drugs that have been approved by the FDA contain chemically modified nucleotides (Figure 1) indicating the critical role chemists have played in bring oligonucleotides from bench to bedside. Importantly, a plethora of different chemically modified nucleotides have been described in the literature

• of chemically modified nucleotides into oligonucleotides is an essential part of their development as therapeutics.

A new building block for DNA network formation by self-assembly and polymerase chain reaction

• Holger Bußkamp,
• Sascha Keller,
• Marta Robotta,
• Malte Drescher and
• Andreas Marx

Beilstein J. Org. Chem. 2014, 10, 1037–1046, doi:10.3762/bjoc.10.104

• different shapes which are further characterized in solution by DLS. EPR measurements further corroborate network formation and suggest rather rigid DNA networks. As demonstrated, the approach allows to additionally modify the networks by using chemically modified nucleotides during PCR. The depicted